From Idea to Market: Product Lifecycle Management in the Pharmaceutical Industry (Market Focus)

Publication Date	July 2007
Publisher	Datamonitor
Product Type	Brief
Pages	11
ISBN Number	not applicable
Product Code	DAT05979

Price

£1,000.00
approximately: $1,766 | €1,268

PDF

PRINT £1,050 ($1,854 | €1,331)

Order above formats by FAX

Summary

Introduction

The pharmaceutical industry produces increasingly complex products, with reduced time-to-market windows, and stringent domestic and international regulatory and compliance requirements. Datamonitor views PLM technology as one of the most rapidly growing market due to its inherent focus on time to market and product development, key business priorities in the pharmaceutical industry.

Scope

Identification and analysis of the business drivers and inhibitors that are impacting PLM adoption in the pharmaceutical industry
Spending by Big Pharma and Biotech on PLM software and services in North America, Western Europe and APAC

Highlights

Product lifecycle management will transform the drug development lifecycle process

PLM addresses key business challenges facing the pharmaceutical industry

Successful PLM for the pharmaceutical industry prevails over several constraining factors

Reasons to Purchase

Understand and evaluate factors that will affect PLM adoption in the pharmaceutical industry
Align your strategy with developments in the pharmaceutical industry
Identify opportunities in an emerging market

Content

Datamonitor View
Catalyst
Summary
Analysis
- Product lifecycle management will transform the drug development lifecycle process
- The nature of a drug's lifecycle necessitates a PLM strategy
- PLM addresses key business challenges facing the pharmaceutical industry
- A greater focus on decreasing time to market is driving adoption of PLM
- Harmonizing product portfolios from M&A activities sets the stage for PLM
- Reducing the challenges and cost associated with regulatory compliance
- The nature of the pharmaceutical drug pipeline is changing
- Complexity of pharmaceutical products is increasing
- The end of the Blockbuster era signifies more candidates in the pipeline
- Successful PLM for the pharmaceutical industry prevails over several constraining factors
- Repurposing software from other industries makes the pharmaceutical industry suspicious
- The traditional autonomous-business-unit mentality inhibits adoption of PLM
- PLM does not mean an antidote to new product development
Actions
- Articulate strategic business benefits of your PLM investment decisions
- Take a holistic approach to PLM
- Understand how PLM changes the lifecycle processes of a pharmaceutical product
Appendix
Appendix
- Definitions
- Abbreviations
- References
- Methodology
- Further reading
- Ask the analyst
- Datamonitor consulting
- Disclaimer
List of Tables
- Table 1: Global PLM spending in the pharmaceutical industry by sector 2006-2012
List of Figures
- Figure 1: The pharmaceutical product lifecycle is highly regulated, more complex and longer than other industries
- Figure 2: Drug discovery licensing dependence of the top 10 pharmaceutical companies
- Figure 3: Drug discovery licensing dependence of the top 10 pharmaceutical companies